CURRICULUM VITAE del Prof. GIUSEPPE LEMBO - ONLUS Futura ...

Cifelli G, Dupont S, Ferrari A, Maffei A, Marino G, Cordenonsi M, Selvetella G, Aretini A, Colonnese C, Bettarini U,Russo G, Fabbro C, Soligo S, Adorno M, Braghetta P, Bonaldo P, Volpin D, Piccolo S, Lembo G, Bressan GM. Cell 2006Mar 7;124(5): 929-42.TELMISARTAN, RAMIPRIL, OR BOTH IN PATIENTS AT HIGH RISK FOR VASCULAR EVENTS. ONTARGETInvestigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. N Engl JMed. 2008 Apr 10;358(15):1547-59.TELMISARTAN TO PREVENT RECURRENT STROKE AND CARDIOVASCULAR EVENTS. Yusuf S, Diener HC,Sacco RL, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST,Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C,Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T, Weber M, Yoon BW; PRoFESSStudy Group. N Engl J Med. 2008 Sep 18;359(12):1225-37.ASPIRIN AND EXTENDED-RELEASE DIPYRIDAMOLE VERSUS CLOPIDOGREL FOR RECURRENT STROKE.Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, BornsteinN, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, HilbrichL, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, Vandermaelen C, Voigt T, Weber M,Yoon BW; PRoFESS Study Group. N Engl J Med. 2008 Sep 18;359(12):1238-51.EFFECTS OF ASPIRIN PLUS EXTENDED-RELEASE DIPYRIDAMOLE VERSUS CLOPIDOGREL ANDTELMISARTAN ON DISABILITY AND COGNITIVE FUNCTION AFTER RECURRENT STROKE IN PATIENTSWITH ISCHAEMIC STROKE IN THE PREVENTION REGIMEN FOR EFFECTIVELY AVOIDING SECONDSTROKES (PROFESS) TRIAL: A DOUBLE-BLIND, ACTIVE AND PLACEBO-CONTROLLED STUDY. Diener HC,Sacco RL, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP,Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M,Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T, Weber M, Yoon BW;Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) study group. Lancet Neurol. 2008Oct;7(10):875-84.RENAL OUTCOMES WITH TELMISARTAN, RAMIPRIL, OR BOTH, IN PEOPLE AT HIGH VASCULAR RISK(THE ONTARGET STUDY): A MULTICENTRE, RANDOMISED, DOUBLE-BLIND, CONTROLLED TRIAL. MannJF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S,Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S; ONTARGETinvestigators. Lancet. 2008 Aug 16;372(9638):547-53.EFFECTS OF THE ANGIOTENSIN-RECEPTOR BLOCKER TELMISARTAN ON CARDIOVASCULAR EVENTS INHIGH-RISK PATIENTS INTOLERANT TO ANGIOTENSIN-CONVERTING ENZYME INHIBITORS: ARANDOMISED CONTROLLED TRIAL. The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjectswith cardiovascular Disease (TRANSCEND) Investigators. Lancet. 2008 Sep 27;372(9644):1174-83PRESSURE-INDUCED VASCULAR OXIDATIVE STRESS IS MEDIATED THROUGH ACTIVATION OFINTEGRIN-LINKED KINASE 1/BETAPIX/RAC-1 PATHWAY. Vecchione C, Carnevale D, Di Pardo A, Gentile MT,Damato A, Cocozza G, Antenucci G, Mascio G, Bettarini U, Landolfi A, Iorio L, Maffei A, Lembo G. Hypertension. 2009Nov;54(5):1028-34.USUAL VERSUS TIGHT CONTROL OF SYSTOLIC BLOOD PRESSURE IN NON-DIABETIC PATIENTS WITHHYPERTENSION (CARDIO-SIS): AN OPEN-LABEL RANDOMISED TRIAL. Verdecchia P, Staessen JA, Angeli F, deSimone G, Achilli A, Ganau A, Mureddu G, Pede S, Maggioni AP, Lucci D, Reboldi G; Cardio-Sis investigators. Lancet.2009 Aug 15;374(9689):525-33.EFFECTS OF HIGH-DOSE VERSUS LOW-DOSE LOSARTAN ON CLINICAL OUTCOMES IN PATIENTS WITHHEART FAILURE (HEAAL STUDY): A RANDOMISED, DOUBLE-BLIND TRIAL. Konstam MA, Neaton JD,Dickstein K, Drexler H, Komajda M, Martinez FA, Riegger GA, Malbecq W, Smith RD, Guptha S, Poole-Wilson PA;HEAAL Investigators. Lancet. 2009 Nov 28;374(9704):1840-8.